: iStockAnalyst.com Symbols Feed

Biotech Industry Overview

Mon, 01 Jun 2009 14:38:59 GMT

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index inc[More...]

Biotech Industry - Industry Outlook

Thu, 16 Apr 2009 20:54:01 GMT

Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See[More...]

Biotechnology Industry - Zacks Analyst Interviews

Fri, 05 Dec 2008 12:44:00 GMT

Historically, the biotech industry was less impacted by market conditions due to its unique characteristics. In large part, biotech stocks have been event-driven. Specifically, investors are more focused on clinical development and pipeline advancement for individual biotech companies. However, current market conditions have exerted a negative impact on the valuation of individual companies in the biotech industry. We believe the different impact current market conditions have exerted is mainly due to the credit crunch. Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by restructuring. Some even have to suspend operations[More...]

Biotechnology Industry

Thu, 04 Dec 2008 20:05:00 GMT

Historically, the biotech industry has been less impacted by market conditions due to its unique characteristics. In large part, biotech stocks have been event-driven. Specifically, investors are more focused on clinical development and pipeline advancement for individual biotech companies. ? However, current market conditions have exerted a negative impact on the valuation of individual companies in the biotech industry. We believe the different impact current market conditions have exerted is mainly due to the credit crunch. Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by[More...]

3SBio: Solid Q3 Results - Analyst Blog

Thu, 13 Nov 2008 21:16:00 GMT

3SBio's (SSRX) third quarter resuts were solid and in line with our expectations on an adjusted basis. Net revenues amounted to RMB68.2 million (US$10.0 million) in the third quarter 2008, compared with RMB56.1 million in the third quarter 2007, representing an increase of 21.6%. The company's flagship product EPIAO is the number 1 brand in the EPO market. Second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company s top line growth. The recent deal with US-based AMAG Pharmaceuticals will boost SSRX expansion into IV Iron market and sustain long term growth. According to our model, 3SBio will enjoy a 38% compound annual growth rate (CAGR) in top line growth, while earnings per share will boast a 16% CAGR in the next four years. In the[More...]

The Week In Review: More Fallout From Economic Crisis

Sun, 09 Nov 2008 17:55:00 GMT

Charles River Labs noted a slowdown in the worldwide CRO business; 3SBio took a $2.7 million writedown in $3 million of Lehman Brothers commercial paper; we presented Part III in our coverage of the most recent proposal for China patent law reform; Simcere Pharma and Tongjitang Chinese Medicines will institute stock buybacks; NeoStem announced acquisition of two of China-based companies; TomoTherapy bought a China company that makes linear accelerators for radiotherapy machines; WuXi PharmaTech signed a new three-year CRO deal with Pfizer; Roche broke ground on an expansion of its Shanghai facilities; BioCurex completed the incorporation process for a fully-owned subsidiary, BioCurex China; and Sinovac Biotech was named to the Deloitte Technology Fast 50 China 2008. More details... Stock Symbols: (NYSE: CRL) (NSDQ: SSRX) (NYSE: SCR) (NYSE: TCM) (AMEX: NBS) (NSDQ: TOMO) (NYSE: WX) (NYSE: PFE) (NSDQ: RHHBY)[More...]

3SBio’s Q3 Hurt by Lehman Bankruptcy

Mon, 03 Nov 2008 23:00:00 GMT

3SBio Inc. announced a $2.7 million writedown as a consequence of the US financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers bankruptcy, the notes have been given a value of $300,000. 3SBio made the announcement as part of its preliminary Q3 unaudited results. The company said its Q3 revenues climbed 22% to 68.2 million RMB ($10.0 million). However, because of the charge, net income dropped to 1.9 million RMB ($0.3 million), or $0.01 per ADS. More details... Stock Symbol: (NSDQ: SSRX)[More...]

Analyst Comments: SMI, Gushan, Priceline, ArthroCare, ZOLL Medical, Orchid Cellmark, Charlotte Russe, Hoku Scientific, 3SBio, Skechers, Coca-Cola Hellenic

Tue, 07 Oct 2008 18:17:00 GMT

Semiconductor Manufacturing International (SMI) is a Chinese semiconductor foundry company with multiple integrated chip wafer fabrication plants. SMI is the largest foundry company in China (third largest worldwide) and operates multiple plants and fabrication (fab) lines. Strategic alliances with Chartered, Toshiba, Infineon (IFX), Fujitsu, Motorola (MOT), Elpida and IMEC have provided access to intellectual property (IP) associated with a variety of semiconductor process technologies. We remain concerned regarding operational performance in the near-term given severe price declines in DRAM. The firm has announced they plan to exit the DRAM business. We[More...]

The Week In Review: Deals, Development And Financials

Sun, 28 Sep 2008 17:54:00 GMT

Phynova will adopt a China-centric business plan; Crown Bioscience will build a second China-located CRO facility in Taicang City; Qiagen and the Chinese Academy of Sciences will develop new molecular tests to determine the safety of food; 3SBio filed for SFDA approval of a high-dose formulation of EPIAO; Sinovac Biotech will develop a vaccine for human hand, foot and mouth disease; China Pharma Holdings hopes to report a positive cash flow in Q3; China Sky One Medical increased its full-year 2008 revenue and income guidance; Tianyin Pharma will migrate to the American Stock Exchange; the International Pharmaceutical Excipients Council (IPEC) China was formed at a critical time for the industry; and new reports showed that the coverup of the baby formula scandal started in late 2007. More details... Stock Symbols: (AIM: PYN) (NSDQ: QGEN) (NSDQ: SSRX) (AMEX: SVA) (OTCBB: CPHI) (NSDQ: CSKI)[More...]

3SBio Files For SFDA Approval Of High-Dose EPIAO

Thu, 25 Sep 2008 17:27:00 GMT

3SBio has filed for SFDA approval of a high-dose, 36,000 IU formulation of EPIAO for the treatment of anemia resulting from chemotherapy. Unlike 3SBio’s other formulations of EPO, this one would be exclusive to the company. A 36,000 IU injection would be administered once every week, a significant advantage over the three-times per week administration of the more common 10,000 IU injections. More details... Stock Symbols: (NSDQ: SSRX)[More...]

China Business Knowledge Launches "China Prospects Forum" -- Dec. 9, 2009, NYC

Mon, 30 Nov 2009 14:48:00 GMT

China Business Knowledge (CBK) (www.chinabusinessknowledge.com) announces the launch of "China Prospects Forum" breakfast series to introduce the New York business and investment communities to the sector of Chinese-based companies trading on the U.S. capital markets.
"Nearly 500 Chinese-based middle-market companies are listed on the U.S. capital markets, entering the market on the OTC BB via reverse mergers," says China Business Knowledge publisher, Janet Stites.
But even with strong revenues, respectable profits and the constant buzz about China business, many of these companies are trading under the radar and are undervalued by investors."

[More...]

Halter USX China Index Up 10.59% for Third Quarter 2009

Wed, 30 Sep 2009 21:46:00 GMT

For the third quarter of 2009, the Halter USX China Index (NYSE Arca: HXC) was up 10.59%.
During the same period, the Dow Jones Industrial Average increased 14.98% and the NASDAQ increased 15.66%.
HXC is also pleased to announce the inclusion of 20 new constituents to its existing index of China-focused, U.S. listed companies including: China Auto Logistics, Inc. (NASDAQ: CALI) an importer, seller, and trader of automobiles; China Integrated Energy, Inc (NASDAQ: CBEH) which engages in the development, exploration, production, and distribution of bio-diesel; China GrenTech Corporation Limited (NASDAQ: GRRF) that is a manufacturer and seller of wireless coverage products and services; China Marine Food Group Limited (AMEX: CMFO) that engages in the processing, distribution, and sale of processed seafood products; China Mass Media Corp. (NYSE: CMM) which operates as an independent television advertising company; China Natural Gas, Inc. (NASDAQ: CHNG) a distributor and seller of natural gas and gasoline to commercial, industrial, and residential customers; China North East Petroleum Holdings Limited (AMEX: NEP) which engages in the exploration and production of crude oil; China Ritar Power Corp. (NASDAQ: CRTP) a designer, developer, manufacturer, and seller of lead-acid batteries; Deer Consumer Products, Inc. (NASDAQ: DEER) which designs, manufactures, and sells home and kitchen electronic appliances; Harbin Electric, Inc. (NASDAQ: HRBN) that engages in the design, development, manufacture, supply, and service of various electric motors; Mindray Medical International Limited (NYSE: MR) which develops, manufactures, and markets medical devices worldwide; NIVS IntelliMedia Technology Group, Inc. (AMEX: NIV) a designer, manufacturer, marketer, and seller of audio and video consumer products; RINO International Corporation (NASDAQ: RINO) that is engaged in the business of environmental protection and remediation; SinoHub Inc. (AMEX: SIHI) which engages in electronic component sales and electronic component supply chain management (SCM) services; Tongxin International Limited (NASDAQ: TXIC) that designs, develops, manufactures, sells, and services engineered vehicle body structures (EVBS) for light, medium, and heavy duty trucks, and light vehicles; Universal Travel Group (AMEX: UTA) a domestic and international airline ticketing service provider, and cargo transportation agency; Changyou.com Limited (NASDAQ: CYOU) which develops and operates online games; Skystar Bio Pharmaceutical Company (NASDAQ: SKBI) that engages in the development, manufacture, and distribution of medicines, vaccines, and other health care and medical care products for poultry, livestock, and domestic pets; Telestone Technologies Corporation (NASDAQ: TSTC) which provides wireless communications coverage solutions; Tianyin Pharmaceutical Company, Inc. (AMEX: TPI) a developer, manufacturer, marketer, and seller of traditional Chinese medicines and other pharmaceuticals; Wuhan General Group, Inc. (NASDAQ: WUHN) which engages in the design, development, manufacture, and sale of industrial blowers for steam-driven electrical power generation plants; and China Agritech, Inc. (NASDAQ: CAGC) which manufactures and sells organic liquid compound fertilizers and related agricultural products.

[More...]

Halter USX China Index Up 40.88% for Second Quarter 2009

Tue, 30 Jun 2009 22:10:00 GMT

For the second quarter of 2009, the Halter USX China Index (NYSE Arca: HXC) was up 40.88%.
During the same period, the Dow Jones Industrial Average increased 11.01% and the NASDAQ increased 20.05%.
HXC is also pleased to announce the inclusion of 19 new constituents to its existing index of China-focused, U.S. listed companies including: Qiao Xing Universal Telephone (NASDAQ: XING) which designs, manufactures, and sells telecommunication terminals and equipment; Xinhua Sports & Entertainment Limited (NASDAQ: XSEL) which engages in the production of television programs, the placement of advertising, the provision of advertising services, market research, and the publication of magazines with a focus on sports and entertainment; China INSOnline Corp.(NASDAQ: CHIO) which operates as an Internet service and media company; China Housing and Land Development, Inc. (NASDAQ: CHLN) which engages in the acquisition, development, management, and sale of commercial and residential real estate properties; China Infrastructure Investment (NASDAQ: CIIC) which engages in the investment, construction, operation, and management of the Pinglin Expressway toll road; China TransInfo Technology Corp (NASDAQ: CTFO) which provides public transportation information systems technology and solutions; Origin Agritech Limited (NASDAQ: SEED) which engages in the research, development, production, sale, and distribution of hybrid crop seeds; Hurray!

[More...]

3SBio Inc. Announces Unaudited First Quarter 2009 Results

Tue, 19 May 2009 20:55:00 GMT

3SBio Inc. , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2009.[More...]

3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor

Tue, 05 May 2009 11:48:00 GMT

3SBio Inc. , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Ernst & Young Hua Ming as the Company's independent registered public accounting firm.[More...]

3SBio Inc. to Report 2009 First Quarter Earnings on May 19, 2009

Mon, 04 May 2009 11:26:00 GMT

Halter USX China Index Announces First Quarter 2009 Results and Adds New Constituents - Mar 31 2009 8:21PM

Wed, 01 Apr 2009 00:16:00 GMT

For the first quarter of 2009, the Halter USX China Index (Amex: HXC) was down 1.18%.
During the same period, the Dow Jones Industrial Average decreased 13.3% and the NASDAQ decreased 3.07%.
HXC is also pleased to announce the inclusion of two new constituents to its existing index of China-focused, U.S. listed companies including: China Techfaith Wireless Communication Technology Ltd. (NASDAQ: CNTF) which is a product provider focused on research and development of cell phone solutions, and Linktone Ltd. (NASDAQ: LTON) which provides entertainment-oriented telecom services to mobile phone users over mobile telecommunications networks.

[More...]

3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results

Wed, 11 Mar 2009 20:56:00 GMT

3SBio Inc. Receives Official Recognition as a 'High-Tech Enterprise'

Thu, 05 Mar 2009 12:25:00 GMT

3SBio Inc. , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that, in accordance with the relevant provisions issued by the Office of Science and Technology, Liaoning Provincial Department of Finance, National Revenue Department in Liaoning Province and Local Revenue Department in Liaoning Province, the Company has been identified as 'high-tech enterprise.'[More...]

3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009

Wed, 25 Feb 2009 11:56:00 GMT

3SBio Inc. , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2008 after the US market closes on Wednesday, March 11, 2009.[More...]